Author Archives: Thomas Payne

TScan Therapeutics Announces Appointment of Barbara Klencke, M.D., to its Board of Directors

By

TScan Therapeutics Announces CEO Transition

By

TScan Therapeutics Announces First Patient Dosed in Phase 1 Umbrella Clinical Trial Evaluating TSC-100 and TSC-101 for the Treatment of Hematologic Malignancies

By

TScan Therapeutics to Participate in the Barclays Global Healthcare Conference

By

TScan Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Highlights Upcoming Milestones

By

TScan Therapeutics to Participate in the Cowen 43rd Annual Health Care Conference

By

TScan Therapeutics Announces Presentation at the H.C. Wainwright Cell Therapy Virtual Conference

By

TScan Therapeutics Announces FDA Clearance of Three Investigational New Drug Applications for the Treatment of Solid Tumors

By

TScan Therapeutics Announces 2023 Clinical Plans and Highlights Recent Progress

By

TScan Therapeutics Presents Phase 1 Umbrella Trial in Progress on HA-1 (TSC-100) and HA-2 (TSC-101) at the 64th American Society of Hematology Annual Meeting 2022

By